AI-Crafted Universal Coronavirus Vaccine Clears First Human Trial

An AI-designed universal coronavirus vaccine completed a Phase 1 trial in 39 healthy adults, showing a 100% safety profile and robust immune responses against diverse coronaviruses. Delivered via a needle-free microfluidic DNA platform, the vaccine targets conserved viral core features rather than mutable surface spikes, signaling a potential shift from variant boosters to a single broad defense. If Phase 2 confirms durability and broad protection, the approach could reshape vaccine design and public health logistics, including reduced cold-chain needs and biomedical waste.